Open an account

Elanco Animal Health

ELAN · NYSE

$22.70−$0.79 (−3.36%)TodayMarket closed ·
Prev close $23.49

About ELAN

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm is engaged in delivering products and services to prevent and treat disease in farm animals and pets. The company serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. The company includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. The company offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. The company offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

Employees
9,400
Headquarters
Indianapolis, Indiana
Listed
Sep 20, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
elanco.com

ELAN key statistics

Market cap
11.34B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.10M
Volume
8.25M
Open price
$23.34
High today
$23.47
Low today
$22.03
52 Week high
$27.98
52 Week low
$19.40

Elanco Animal Health (ELAN) at a glance

As of Oct 20, 2026, Elanco Animal Health (ELAN) shares are priced at $22.70, giving the company a market cap of 11.34B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $22.03 and $23.47. The current price is 3.0% above the day's low and 3.3% below its high.

Volume so far is 8.25M shares, above the average of 5.10M shares a day.

Over the past year Elanco Animal Health has ranged from $19.40 to $27.98, and now sits 38% of the way up that range.

Elanco Animal Health met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.34 per share against an estimate of $0.2747.

The average analyst price target is $31.52, 38.9% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

82%of 11 analyst ratings say Buy
  • Buy81.8%
  • Hold18.2%
  • Sell0.0%
Price target · 15 analystsAvg $31.52
Low
$26.26
Now
$22.70
High
$35.70

ELAN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 21.5% on average.

  1. Q3 FY24: reported $0.13 per share against an estimate of $0.1205
  2. Q4 FY24: reported $0.14 per share against an estimate of $0.1533
  3. Q1 FY25: reported $0.37 per share against an estimate of $0.3162
  4. Q2 FY25: reported $0.26 per share against an estimate of $0.1993
  5. Q3 FY25: reported $0.19 per share against an estimate of $0.1329
  6. Q4 FY25: reported $0.13 per share against an estimate of $0.113
  7. Q1 FY26: reported $0.40 per share against an estimate of $0.3528
  8. Q2 FY26: reported $0.34 per share against an estimate of $0.2747

ELAN news

  • Elanco Animal Health Reports Q2 2026 Results: Full Earnings Call Transcript

  • Press releasePRNewswire

    Elanco to Participate in BofA Securities Global Healthcare Conference 2026

  • Press releasePRNewswire

    Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care

  • Press releasePRNewswire

    Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

  • Press releasePRNewswire

    Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

  • Press releasePRNewswire

    Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

  • Avi Kapoor

    Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’

  • Press releasePRNewswire

    Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Similar companies

Companies in the same industry as Elanco Animal Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.